跳至主要内容
临床试验/NCT02294344
NCT02294344终止不适用

A Prospective, Controlled Study of Double Filtration Plasmapheresis (DFPP) in Patients With Antineutrophil Cytoplasmic Autoantibody Associated Glomerulonephritis (AAGN)

Zhi-Hong Liu, M.D.1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2014年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
发起方
入组人数
14
试验地点
1
主要终点
the renal recovery rate

研究概览

简要总结

The clinical efficacy of double filtration plasmapheresis(DFPP) in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).

详细描述

This is a single center, prospective, randomized,controlled study to compare the clinical efficacy of double filtration plasmapheresis (DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy versus IV-CTX pulse therapy in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • a diagnosis of ANCA associated vasculitis(AAV), using criteria adapted from the disease definitions of the Chapel Hill consensus conference
  • serum positive ANCA and the ANCA level ≥100 relative unit/ml
  • with renal involvement and serum creatinine≥3 mg/dl
  • written informed consent had been provided.

排除标准

  • other secondary vasculitis
  • anti-glomerular basement membrane(GBM) positive
  • severe infection; hepatitis B antigenemia, anti- hepatitis C virus
  • immunodeficiency; or immunoglobulin G(IgG)<2g/l
  • life threatening
  • renal biopsy show globally sclerotic glomeruli>60% and normal glomeruli<10%
  • need renal replacement therapy for more than 4w
  • received large dose of methylprednisolone(MP),CTX,mycophenolate mofetil(MMF), plasmapheresis or intravenous immunoglobulin(IVIg) therapy.

研究组 & 干预措施

DFPP&CTX

Experimental

double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP&CTX)

干预措施: DFPP&CTX (Other)

cyclophosphamide

Active Comparator

cyclophosphamide(CTX) pulse therapy

干预措施: CTX (Drug)

结局指标

主要结局

the renal recovery rate

时间窗: 3 months

the renal recovery rate at 3 mo defined by dialysis independence and the SCr \<5mg/dl for the patients needed renal replacement therapy at the basement, or the SCr decreased more than 30% of the baseline and the urine sediment red blood cell less than 50\*104/ml for the patients without renal replacement at the basement.

次要结局

  • kidney survival(12 months)

研究者

发起方
Zhi-Hong Liu, M.D.
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Zhi-Hong Liu, M.D.

Professor

Nanjing University School of Medicine

研究点 (1)

Loading locations...

相似试验